Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Could this be the telehealth breakout Wall Street is underestimating?

The stock remains very volatile.

Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales

The telehealth platform is growing quickly but is in the middle of a legal battle.

From overvalued stocks to outsize returns, some capital compounders keep breaking the mold.

The healthcare company is experiencing excellent sales growth, but investors are concerned about its longer-term prospects.

Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks involved in this insightful analysis.

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

Hims & Hers falls into a buying opportunity followng the Q2 release and guidance update but investors shouldn't rush to get in, wait for this market to bottom.

The company says it's working to ensure patients only receive semaglutide produced by Novo Nordisk.

These growth stocks come from completely different industries, but each has something to offer long-term investors.

The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance.

A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red.

Hims & Hers stock fell sharply Tuesday after the company missed Q2 revenue estimates, despite strong growth and reaffirmed guidance.

The latest earnings season, spanning late July and early August 2025, has painted a vivid picture of a bifurcated market, where the titans of technology continue to defy gravity, largely propelled by their aggressive and strategic investments in Artificial Intelligence (AI). While companies like Amazon, Apple, Meta, and Microsoft reported

The U.S. stock market experienced a turbulent start to August 2025, marked by significant declines for several prominent companies. This downturn, following a volatile end to July, has left investors grappling with mixed signals and heightened uncertainty. While the broader market saw a rebound in early August, driven by

Hims & Hers stock just got cheaper -- and it's still too expensive to buy.

Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc.

HIMS stock was down 13% after the company reported earnings.

Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, including regulatory complexity.

These stocks have decades of compounding growth ahead.

Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings